Huma’s platform is ready to use, reducing the time and cost for other companies to bring regulated SaMD products to market, democratising digital health innovation across the industry
Class IIb certification expands the patient population and level of disease severity that can be managed; allowing delivery of personalised care through the use of predictive algorithms
Clinical evidence from over 20 peer-reviewed publications and studies were submitted for regulatory assessment of clinical safety and efficacy
